ArticleFrontiers in oncology2012
Isolation and characterization of circulating tumor cells in prostate cancer.
Article in Frontiers in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.BMC cancer · 2019Trial
- Androgen Receptor Variant 7 (AR-V7) Transcript Expression in Circulating Tumor Cells.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Clinical significance and heterogeneity of circulating tumor cells and clusters in breast cancer subtypes.PeerJ · 2025Review
- Nurturing the marriages of urinary liquid biopsies and nano-diagnostics for precision urinalysis of prostate cancer.Smart medicine · 2023Review
- [Recent advances in isolation and detection of circulating tumor cells with a microfluidic system].Se pu = Chinese journal of chromatography · 2022Review
- Circulating Tumour Cells Indicate the Presence of Residual Disease Post-Castration in Prostate Cancer Patient-Derived Xenograft Models.Frontiers in cell and developmental biology · 2022Article
- Article
- Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma.Scientific reports · 2021Article
- Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.Endocrinology · 2020Article
- Development and Clinical Prospects of Techniques to Separate Circulating Tumor Cells from Peripheral Blood.Cancer management and research · 2020Review
- Association of Monoamine Oxidase A with Tumor Burden and Castration Resistance in Prostate Cancer.Current therapeutic research, clinical and experimental · 2020Article
- Liquid biopsy in pancreatic cancer: the beginning of a new era.Oncotarget · 2018Review
- Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.BJU international · 2017Article
- Article
- Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment.Journal of translational medicine · 2016Article
- Circulating Tumor Cells: When a Solid Tumor Meets a Fluid Microenvironment.Advances in experimental medicine and biology · 2016Article
- Nanotechnology for enrichment and detection of circulating tumor cells.Nanomedicine (London, England) · 2015Review
- Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.The Journal of molecular diagnostics : JMD · 2015Review
- Using circulating tumor cells to inform on prostate cancer biology and clinical utility.Critical reviews in clinical laboratory sciences · 2015Review
- Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer.BMC cancer · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledCirculating tumor cells (CTCs) are tumor cells found in the peripheral blood that putatively originate from established sites of malignancy and likely have metastatic potential. Analysis of CTCs has demonstrated promise as a prognostic marker as well as a source of identifying potential targets for novel therapeutics. Isolation and characterization of these cells for study, however, remain challenging owing to their rarity in comparison with other cellular components of the peripheral blood. Several techniques that exploit the unique biochemical properties of CTCs have been developed to facilitate their isolation. Positive selection of CTCs has been achieved using microfluidic surfaces coated with antibodies against epithelial cell markers or tumor-specific antigens such as EpCAM or prostate-specific membrane antigen (PSMA). Following isolation, characterization of CTCs may help guide clinical decision making. For instance, molecular and genetic characterization may shed light on the development of chemotherapy resistance and mechanisms of metastasis without the need for a tissue biopsy. This paper will review novel isolation techniques to capture CTCs from patients with advanced prostate cancer, as well as efforts to characterize the CTCs. We will also review how these analyzes can assist in clinical decision making.
conclusionThe study of CTCs provides insight into the molecular biology of tumors of prostate origin that will eventually guide the development of tailored therapeutics. These advances are predicated on high yield and accurate isolation techniques that exploit the unique biochemical features of these cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.